Summary: Presently, allergic diseases can be effectively managed with numerous therapeutic options. However, all available pharmacotherapeutics work only on the symptoms and fail to provide a long-term effect. As the only causative, disease-modifying treatment, allergen immunotherapy (AIT) is the only option with potential to “cure” the disease and provide relief even after cessation of treatment. In this article, we review recent advances in various routes of allergen immunotherapy. With an increasing availability and standardization of component-resolved diagnostics, we are able to better identify and qualify patients fit for immunotherapy, even in the presence of multisensitization. The already-excellent efficacy of AIT is predicted to improve even further with new ways of administering the allergen extract, most importantly due to intralymphatic and intradermal immunotherapy. While those methods are still in clinical trials, the results published thus far shows a great potential to improve the effectiveness and compliance of patients undergoing AIT. Finally, we discuss the availability of subcutaneous and sublingual treatments on the Polish market, which has been turbulent in the last few years.